Consolidated Statements of Cash Flows - USD ($)	12 Months Ended
	Dec. 31, 2015	Dec. 31, 2014
Cash flows from operating activities
Net (loss) income	$ (516,000)	$ 23,109,000
Adjustments required to reconcile net income to net cash used in operating activities:
Change in fair value of warrant liability	(610,000)	(9,455,000)
Change in fair value of Series B preferred stock derivative liability	(9,330,000)	(27,764,000)
Gain on re-valuation of liquidated damages liability	(120,000)
Warrants issued to placement agents	213,000
Deferred taxes	(73,000)
Amortization of patents	31,000	31,000
Depreciation	299,000	127,000
Stock-based compensation	479,000	775,000
Stock-based compensation - severance	4,000	1,161,000
Changes in operating assets and liabilities net of acquisitions:
Accounts receivable	(25,000)	(92,000)
Accounts payable, accrued expenses, deferred revenue and other	296,000	(977,000)
Accrued severance	(247,000)	555,000
Prepaid expenses and other current assets	(182,000)	(42,000)
Net cash used in operating activities	(9,781,000)	(12,572,000)
Investing activities:
Purchases of property and equipment	(210,000)	(1,202,000)
Net cash used in investing activities	(210,000)	(1,202,000)
Financing activities:
Proceeds from warrant exercises	396,000
Proceeds from issuance of common stock, net	12,384,000
Net cash provided by financing activities	12,780,000
Net increase (decrease) in cash and cash equivalents	2,789,000	(13,774,000)
Cash and cash equivalents, beginning of period	6,581,000	20,355,000
Cash and cash equivalents, end of period	9,370,000	6,581,000
Supplemental schedule of non-cash financing activities:
Accretion of Series B redeemable convertible preferred stock	$ 10,278,000	1,285,000
Fair value of warrant liability upon issuance	4,210,000
Fair value of warrant liability converted upon exercise	$ 1,073,000	$ 1,595,000